EndoLipiD Therapeutics

Executive Summary

EndoLipiD Therapeutics is a Spanish biotechnology company spun out of the Vall d'Hebron Research Institute in 2021, focused on developing peptide-based therapies that mimic Sex Hormone-Binding Globulin (SHBG) to reduce ectopic fat accumulation. The company's platform targets metabolic and aesthetic conditions, with lead programs in non-alcoholic steatohepatitis (NASH) and cellulite. By leveraging SHBG's role in regulating fat metabolism, inflammation, and fibrosis, EndoLipiD aims to address high unmet needs in these large markets. Currently in the preclinical stage, the company has not disclosed its total funding or valuation.

Upcoming Catalysts (preview)

• Q1 2027Completion of GLP-toxicology studies40% success
• Q4 2027IND/CTA filing for NASH program20% success
• Q2 2027Partnership or licensing deal for cellulite program25% success